Endoluminal Suturing Devices Market Size, Share & Trends Analysis Report By Application (Bariatric Surgery, Gastrointestinal Surgery, Gastroesophageal Reflux Disease Surgery, Others), By End Use (Hospitals, Ambulatory Surgical Centres, Other) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global endoluminal suturing devices market size was valued at USD 53.04 million in 2021 and is predicted to reach at USD 146.38 million by 2030, increasing at a CAGR of 11.94% from 2022 to 2030.

Obesity is now a global pandemic that affects millions of people throughout the world, and bariatric endoscopies are becoming increasingly popular as a treatment option in healthcare settings. Suturing as well as stapling devices are most commonly utilised in the treatment of GERD and obesity. The main advantage of using these devices is that they allow for minimally invasive clinical treatments.

Clinical procedures as well as clinical trials have traditionally progressed at a slower rate than in recent years because to enormous improvements. Endoluminal suturing devices are frequently used in endoscopic procedures to implant thick sutures at the desired area with the aid of flexible sutures. a small, specialised suturing tool used during endoscopic surgery that is characterised by its pliability. Medical operations that use endoluminal suturing devices result in a better patient satisfaction, faster recovery time, reduced hospital visits, and shorter length of stay in medical facilities because of the desire for minimally invasive procedures. Advances in instrumentation have made endoluminal suturing devices more widely accepted.

Market Dynamics

Global endoluminal suturing devices market drivers

A greater number of people suffering from gastrointestinal conditions will drive up demand

In the year 2020, the GI defects market category was responsible for 24.5 million USD. The growing incidence of gastrointestinal disorders will bolster consumer interest in endoluminal suturing device goods and enhance the value of the business. A chronic disease known as functional gastrointestinal disorder (FGID) is characterized by severe symptoms such as acid reflux, dyspepsia, heartburn, chronic constipation, irritable bowel symptoms, bloating, and abdominal distention. These symptoms can be present at any time during the disease's course.

The symptoms can appear anywhere along the gastrointestinal tract, from the top part (the esophagus and stomach) all the way down to the bottom part (intestine). According to the findings of a recent survey conducted on an international scale, approximately forty percent of the adult global population is affected by functional gastrointestinal illnesses of varied degrees of severity. There is a correlation between having this disease and having a markedly diminished quality of life. In addition, an increase in the prevalence of gastrointestinal disorders all over the world will contribute further to an expansion of the market for endoluminal suturing devices.

Physical inactivity and weight gain are predicted to be major growth drivers

The sedentary way of life is likely to boost the market's growth even further. According to the World-Health-Organization (WHO), inactive habits kill an estimated 5.3 million people worldwide each year, with at least 300,000 of these deaths occurring in the United States alone. More than a third of American youngsters eat junk food on a regular basis, which can lead to diabetes, overweight, cardiovascular problems and other health issues, according to research from the CDC. According to the US Department of Health & Human Services, barely one third of American youngsters participate in some form of physical activity each day. As a result, a more sedentary lifestyle will lead to an increase in heart difficulties, which will lead to an increase in the demand for clinical nutrition.

According to a recent WHO assessment, the global obesity incidence has more than tripled since 1975. As of 2016, there were more than 1.9 billion adults aged 18 and older who were overweight or obese, and more than a third of those people were considered obese. In addition to increasing the likelihood of different health problems as a result of obesity, these variables are expected to spur demand for endoluminal suturing devices.

Global endoluminal suturing devices market restraints

In developing countries, there is less of an acceptance for bariatric procedures

The expansion of the market for endoluminal-suturing-devices has been slowed down as a result of the stringent rules that are linked with bariatric as well as metabolic operations (BMS). For instance, the governments of developing nations have instituted severe rules on medical devices that are involved with bariatric procedures. In addition, health insurance typically only reimburses or covers the cost of the procedure at a rate of thirty percent. Because of this, the market has been moving in an unfavorable direction, and it will continue to do so in the future, which will slow the overall advancement of the sector. During the time covered by this estimate, the industry revenue generated by endoluminal suturing devices is expected to be hindered by scenarios in which insurance coverage is lower in developing nations.

Global endoluminal suturing devices market key opportunities

Advent of new opportunities due to endoluminal suturing robotics is expected

As a solution to issues such as the limited space in which endoluminal suturing devices can be used, error reduction, and the ability to replicate the movement of a human wrist, robotic surgery has been proposed. The use of robotics also allows surgeons with greater control over their robotic arm and three-dimensional vision. Endoluminal suturing is becoming increasingly robotic as a consequence of the above considerations. There is a considerable number of patients in the hospital receiving gastrointestinal medicines that necessitate the use of endoluminal suture devices. There will be an increase in endoluminal suturing devices market growth as a result of the inclusion of robotics in endoluminal-suturing-devices.

For obesity control, endoluminal suturing devices have been adopted to a large extent due to the development of minimally invasive operations. It has been shown that endoluminal therapies like MSA as well as Esophy-X (or transoral incision-less fundoplication) are well-received by patients and provide a long-term benefit. Aside from the increasing prevalence of obesity-related health issues, gastrointestinal issues, and other morbidities, a personalized approach is needed to address them. As a result, new and profitable market opportunities are projected to open up as a result of increased investment in medical device development.

Regional Analysis

The global endoluminal suturing devices market is segmented by geography into North America, Europe, Asia-Pacific (APAC Region), Latin America, and Middle East & Africa (MEA).

In 2021, North America held a dominant position in the market for endoluminal suturing devices and was responsible for more than 45% of the revenue share. This is as a result of the availability of a sizable patient pool as well as advantageous reimbursement policies. It is anticipated that an increase in the number of bariatric procedures will have a direct and beneficial impact on the expansion of the marketplace for endoluminal-suturing-devices.

The American Society for Metabolic & Bariatric Surgery estimates that there were around 252,000 bariatric surgery operations performed in the United States in 2018, which represents a significant increase from the 158,000 treatments that were conducted in 2011.

The marketplace for endoluminal-suturing-devices is predicted to develop at the quickest pace in Asia Pacific owing to the existence of a vast population that is prone to a variety of chronic diseases and the presence of an improved healthcare infrastructure.

The prevalence of gastrointestinal diseases across the region is on the rise as a direct result of increasing urbanization, as well as a number of other environments as well as lifestyle factors that are undergoing significant shifts. In addition, developing countries like India and China are seeing significant demand for minimally-invasive-surgeries due to the rise of a variety of chronic and infectious disorders.

Segmental Analysis

The global endoluminal suturing devices market is divided into different segments according to Application, End Use, and Region (Geography).

By Application, the global market is segmented into Bariatric Surgery, Gastrointestinal Surgery, Gastroesophageal Reflux Disease Surgery, and Others. This segment accounted for nearly 37% of the total market share in 2021, making it the most dominant segment. In part, this is due to a rise in the number of gastrointestinal procedures and a wide variety of applications in the domain of gastroenterology. The pancreas, liver, biliary system, oropharynx, as well as alimentary canal are just some of the organs affected by this disease. More than 60.0 million Americans are diagnosed with a digestive disorder each year, as per the Gastroenterology Associates of Pensacola.

Gastroesophageal-reflux-disease (GERD) is one of the fastest-growing medical specialties, thanks to rising disease prevalence and advances in surgical technology. 8.9 million medical visits and an estimated yearly cost of USD 24.0 billion in 2017 were attributed to GERD, as per the Society of American Gastrointestinal & Endoscopic Surgeons. Aside from the fact that this condition is generally life-long, it is also linked to other health issues, such as esophageal stricture, adenocarcinoma, as well as esophagitis. Because endoluminal suturing is a popular treatment for this illness, the endoluminal suturing device market is likely to grow at a rapid pace over the forecast period.

As obesity rates rise and the number of bariatric surgery treatments rises, this market sector also has a sizable proportion. In addition to gastric bypass, sleeve, and balloon procedures, physicians now perform gastric revision, small gastric bypass, and endoscopic sleeve procedures. A total of 685,874 bariatric procedures were carried out in 2016, as per the International Federation for such Surgery of Obesity & Metabolic Disorder (IFSO). Endoluminal suturing devices are benefiting from an expanding bariatric surgery market as obesity rates rise and technology improves the effectiveness of various bariatric surgical methods.

By End Use, the global market is segmented into Hospitals, Ambulatory Surgical Centers, and Others. In 2021, hospitals accounted for over 70% of total market revenue, and this dominance is expected to persist over the forecast timeframe. Chronic disease and bariatric surgery are both increasing in prevalence. Endoluminal suturing devices are also benefiting from an expanding patient base and better healthcare infrastructure. There is also a growing demand for endoluminal suturing devices in developed nations like the US, where there are a large number of trained healthcare professionals.

Because of the increase in the proportion of minimally invasive procedures, the ambulatory surgical center market is expanding at the fastest rate. Endoluminal surgery advancements in technology are allowing more procedures to be performed as outpatient procedures. Because these surgical centers charge much less than hospitals do, patients and insurance companies alike can save a lot of money.

By Region or Geography, the global market is segmented into North America, Europe, Asia-Pacific (APAC Region), Latin America, and Middle East & Africa (MEA). Over half of the revenue in the endoluminal-suturing-devices market was held by North America by 2021. A huge patient population and attractive reimbursement rules are to blame for this. Increasing healthcare infrastructure and a big population at risk for a variety of chronic diseases will drive endoluminal suturing device sales in Asia Pacific, according to industry analysts.

Recent Developments

• July 2022 - With the help of Amazon Web Services' (AWS) Health Equity Initiative, Medtronic, a leading company in medical technologies, and the American-Society-for-Gastrointestinal-Endoscopy have announced plans to expand the Medtronic-Health-Equity-Assistance-Program for colon cancer screening across the United States.
• May 2022 - After signing a new distribution deal, Aesculap and True Digital Surgery have strengthened their long-term relationship in robotically-controlled-3D-digital visualisation. The Aesculap Aeos® electronic surgical microscope has now been granted exclusive distribution rights by Aesculap for a long period of time. Aesculap AG with True Digital Surgery, Inc. signed a contract.